Pseudomonas Aeruginosa Clinical Trial
Official title:
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
This dose escalation safety study will evaluate several doses of RSP-1502 or active control administered by inhalation for 14 days. Following determination of the MTD, a dose expansion cohort will receive RSP-1502 at the MTD versus active control administered by inhalation for 14 days. All subjects will be followed for 14 days after completion of dosing. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04335383 -
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
|
||
| Not yet recruiting |
NCT06035055 -
Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis
|
Phase 4 | |
| Completed |
NCT00774072 -
Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
|
Phase 2 | |
| Completed |
NCT00515229 -
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
|
Phase 2 | |
| Terminated |
NCT00333385 -
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
|
Phase 4 | |
| Recruiting |
NCT03638830 -
Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
|
Phase 2 | |
| Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
| Completed |
NCT00633191 -
Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00712166 -
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
|
Phase 3 | |
| Recruiting |
NCT04171817 -
Animal-Assisted Visitation Program Chlorhexidine Trial
|
Phase 4 | |
| Completed |
NCT02696902 -
Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
|
Phase 2 | |
| Completed |
NCT01319253 -
A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
|
N/A | |
| Recruiting |
NCT05282082 -
Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
|
||
| Recruiting |
NCT04803695 -
Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
|
||
| Not yet recruiting |
NCT05632315 -
PMT for MDRO Decolonization
|
Phase 2 | |
| Completed |
NCT01055847 -
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
|
Phase 2 | |
| Completed |
NCT01745796 -
Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)
|
||
| Recruiting |
NCT04673175 -
Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Terminated |
NCT05210387 -
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
|
N/A | |
| Recruiting |
NCT05616221 -
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
|
Phase 2 |